Research in recent years is still characterized by a wide range (from 2 days to several weeks of monitoring) of schedules used. However, progress has led to evidence-based HBPM protocols anchoring modern hypertension management strategies.

The scientific trajectory began in 1986 with the Ohasama study, which pioneered the use of population-based cohorts to bypass the “white-coat effect” through self-measurement. This advanced in 1991 with automated monitors, enabling laypeople to perform accurate readings without professional training. By 1998, Ohasama data confirmed HBPM’s superior prognostic value.

Subsequent research has focused on determining the “optimal” number of readings required for a patient’s true risk profile. Studies such as SHEAF (2004) emphasized that multiple readings per occasion were necessary to mitigate the initial “alerting response” from cuff inflation. The Didima study showed prognostic value increased with the monitoring duration. While 12 to 16 readings capture significant data, a 7-day schedule provides superior diagnostic consistency. The IDHOCO meta-analysis of over 4,800 participants proved that agreement on hypertension phenotypes reached near-perfect levels after the 6th day, establishing the 7-day duration as optimal. This provides scientific basis for a 7-day monitoring schedule as the gold standard.

The protocol distills decades of research. While the 7-day, twice-daily, duplicate-reading model emerged from global research, the specific branding and systematic clinical adoption of the term “722” are most associated with the Taiwan Hypertension Society and the Taiwan Society of Cardiology. The 722 protocol is structured as a mnemonic:

• 1. “7” (Duration): Ensures a reliable estimate of the underlying BP and captures day-to-day variability

• 2. “2” (Occasions): Two occasions daily, once in the morning and once in the evening.

• 3. “2” (Readings): Taken 1 min apart to reduce bias from the elevation often seen in the first reading.

The term “722” was developed to improve public awareness, with early public health campaigns launching the “722 GO for Health” initiative to promote healthy lifestyles. Adjustments are recommended for specific conditions; patients with atrial fibrillation should have 3 or more readings per occasion to account for increased beat-to-beat variability.

A significant recent developments in HBPM study is the investigation of how long-term monitoring affects the reading stability and the validity of the established protocols. This has been explored most comprehensively in the TASMINH4 trial, with a secondary analysis published in 2025.

A long-standing debate in HBPM methodology is the necessity of “discarding the first day” of BP monitoring. The European Society of Hypertension (ESH) guidelines have recommended this practice since 2008 to account for the instability of initial readings. However, the TASMINH4 analysis suggests that this phenomenon is subject to physiological habituation. The trial found that in the first 3 months of monitoring, day 1 readings were significantly higher than readings on subsequent days, with a mean systolic difference of 1.1 mmHg compared to day 2 and up to 3.5 mmHg compared to day 7. This confirms the “alerting response” in novices. However, after 6 months of monitoring experience, this difference became statistically insignificant. The study also demonstrated that intra-week BP variability significantly decreased over time as patients became accustomed to the monitoring process.

These findings provide a scientific rationale for tiered monitoring recommendations based on patients’ experiences. For patients at the point of initial diagnosis (the “novice” phase), a full 7-day schedule with the first day discarded is appropriate. However, for “experienced” patients in the long-term follow-up phase (e.g., those who have been monitored for more than 6 months), an abbreviated 3-day schedule that includes the first day may be clinically sufficient without significantly altering treatment decisions. This distinction is critical for reducing patient burden and improving long-term adherence to self-monitoring.

In the Japanese community, the Ohasama study showed that day-to-day morning home systolic BPV is a superior predictor of cardiovascular mortality and cognitive decline versus office-based measurement. A reference value of 8.5% for the coefficient of variation (CV) has been proposed as a clinical threshold for identifying high-risk individuals.

For patients in high-risk clinical settings, BPV is crucial for immediate survival. In patients undergoing hemodialysis, increased interdialytic home systolic BPV is significantly associated with higher all-cause mortality and cardiovascular death. These patients experience massive fluid shifts and autonomic dysfunction, leading to heightened variability tertiles correlating with age, diabetes mellitus, and visceral fat.

In nursing home residents, high systolic BPV is associated with increased falls and shorter duration between consecutive fall events. This suggests that BP instability may contribute to orthostatic intolerance or transient cerebral hypoperfusion, leading to physical trauma in older adults.

Longitudinal survival analysis in memory clinics further revealed a time-sensitive prognostic window. While BPV may not predict 5-year mortality across the clinical population, increased morning systolic HBPV indicates of mortality within the first year of follow-up. In patients with dementia, evening-to-evening systolic HBPV strongly predicts mortality.

A breakthrough in stroke risk assessment is the identification of “peak home blood pressure” as a novel risk factor. In the J-HOP extended study, the Average Peak Home SBP was a stronger and earlier predictor of stroke than traditional variability indices. Patients with peak BP values ≥173 mmHg had a 4.39-fold increased stroke risk, which was significant even after adjusting for average BP. This study identified a 176 mmHg threshold for the 5-year stroke risk, suggesting that extreme hemodynamic peaks damage the cerebral vasculature.

Peak nighttime home SBP independently predicted stroke incidence, emphasizing the risk posed by nocturnal hypertension. A threshold of 136 mmHg identifies risky surges linked to autonomic dysfunction or sleep-disordered breathing.

The consistency of BP control over time, quantified as TTR, has emerged as a vital indicator. In a post hoc analysis of the SPRINT trial, a TTR of 70% to 100% was associated with a 35% reduction in cardiovascular events. The J-HOP study validated TTR as an independent stroke predictor, identifying a 67% threshold for a lower risk. Each 10% decrease in home SBP TTR was associated with a 9% increased stroke risk.

Cross-sectional studies have provided insights into HBPV and HMOD association, showing that high HBPV correlates with subclinical disease markers, even in the absence of clinical cardiovascular events.

A central cross-sectional finding is the relationship between HBPV and arterial stiffness. ^, Using carotid-femoral pulse wave velocity, researchers found that arterial stiffness traits were significantly associated with the ARV of home SBP. This relationship is important because arterial stiffness is a potential mechanism through which BPV damages the cardiovascular system; a stiffer vascular tree has a reduced capacity to buffer pressure fluctuations, leading to increased pulsatile stress on the microvasculature.

The classification of BP into phenotypes, such as white-coat, masked, and sustained hypertension, reveals how variability differs significantly across distinct clinical presentations. A cross-sectional analysis of 107,294 individuals in Brazil showed that BPV levels depend heavily on the classification criteria used (ACC/AHA or ESH). A “U-shaped” relationship exists between BPV and the difference between office and home readings, meaning that the larger the discrepancy between the clinic and home environments, the higher the intrinsic HBPV. Patients managed in the public health system in Brazil had higher rates of uncontrolled hypertension and obesity than those in private referral centers, suggesting that socioeconomic and systemic factors also influence hemodynamic control.

Cross-sectional studies on brain health have identified evening systolic BPV as a marker of cerebral small vessel disease (cSVD). In a memory clinic population, a higher evening systolic CV was associated with a higher total cSVD score, which includes lacunes, white matter hyperintensities, cerebral microbleeds, and enlarged perivascular spaces. This suggests that evening fluctuations, which are more susceptible to the cumulative stressors of the day, may be particularly damaging to the cerebral microvasculature. Similarly, morning diastolic BPV was significantly associated with a higher burden of cerebral microbleeds (>10 microbleeds) in hypertensive patients.

The interplay between respiratory health and BP stability is critical to neurocognitive research. OSAHS is associated with increased beat-to-beat and asleep reading-to-reading variability. Interestingly, while OSAHS severity is linked to short-term hemodynamic instability, it is not significantly associated with long-term day-to-day variability, suggesting that OSAHS damage is primarily mediated through acute nocturnal surges.

Cognitive impairment affects 75% maintenance hemodialysis patients. Higher home systolic BPV is an independent risk factor for cognitive decline, along with advanced age and lower education levels. This mirrors the findings in the broader aging population, where day-to-day BPV predicts dementia risk and cognitive performance.

In the kidneys, HBPV is associated with lower estimated glomerular filtration rates. In a Swedish study of primary care patients, high systolic BPV was a marker of renal dysfunction and increased pulse pressure, indicating a parallel relationship between renal and vascular aging. In populations with severe vascular pathology, such as asymptomatic intracranial artery stenosis, strictly measured office BP and home BP show comparable associations with disease presence, although ambulatory indices, such as nocturnal dipping and morning surges, provide unique prognostic information independent of mean BP levels.

BPV is driven by a complex set of environmental, behavioral, and physiological factors. Identifying these determinants is essential for developing targeted interventions to stabilize BP.

The impact of temperature on BP has been a recurring theme in the literature. A study of middle-aged and elderly residents in Chengdu, China, demonstrated a significant negative correlation between morning indoor temperature and SBP. Specifically, for every 1°C decrease in morning temperature, the SBP increased by 0.39 mmHg. This effect was nonlinear, with the most dramatic increases (2.1 mmHg per 1°C drop) occurring when indoor temperatures fell below 12°C. Morning temperature fluctuations > 1.1°C were identified as an independent driver of increased HBPV, suggesting that maintaining an indoor thermal environment above 18°C is vital for aging populations.

In a longitudinal analysis across seasons, researchers investigated whether seasonal temperature changes affect variability indices. Although office, home, and daytime ambulatory BP levels were lower in summer than in winter (p <0.01), the variability indices (SD, CV, and ARV) for home and ambulatory measurements remained stable across seasons. This implies that while BP levels are sensitive to external cold, BP variability may be an intrinsic physiological trait of the individual. Subanalyses of the REVERENT trial support the consistency of out-of-office measurements over office-based readings for BPV assessment.

In addition to the external climate, internal physiological processes significantly influence hemodynamic stability. A novel finding in recent years is the association between defecation status and BPV. A study analyzing longitudinal data found that the absence of daily bowel movements independently predicted increased CV and SD of home SBP after 1 year. This relationship persisted even after adjusting for age, sex, and medication status, suggesting that constipation-related straining or autonomic alterations may contribute to long-term BPV.

Dietary interventions have also been explored for reducing HBPV. A phase I clinical trial demonstrated that using a low-sodium substitute salt (18% sodium) reduced overall BP without increasing variability. Salt substitution reduced evening systolic BPV, suggesting that sodium restriction may stabilize diurnal BP profile.

Lifestyle and demographic factors further complicate HBPV profiles. Older age, female sex, obesity, and a high heart rate are consistently associated with higher BPV. In a Swedish cohort, high HBPV was linked to smoking and lower alcohol consumption, although the latter may reflect a “sick quitter” bias.

The ultimate goal of HBPV research is to inform clinical practice and healthcare policy by identifying effective pharmacological agents and evaluating patient monitoring systems.

A retrospective study of 36,153 Chinese patients with primary hypertension evaluated the efficacy of amlodipine-based therapy. The study found that although BP control and TTR generally decline with age, amlodipine effectively reduced BPV and increased the time patients spent in the target range across all age groups. The greatest improvements in TTR were noted in younger (18 to 45) and middle-aged (46 to 64) patients, highlighting early intervention benefits. In this comparative evaluation, losartan was the most prescribed blocker but appeared less efficient at controlling BP, possibly due to its shorter half-life compared to telmisartan. This underscores the importance of using long-acting medications to achieve 24-hour hemodynamic stability. Furthermore, single-pill combinations of cilnidipine and valsartan reduce morning home systolic BPV, providing targeted protection against morning surge-related events.

The clinical and economic implications of HBPV monitoring extend to the assessment of healthcare quality. Currently, the Healthcare Effectiveness Data and Information Set metrics and Medicare Advantage “Star” ratings rely heavily on a single “most recent” OBPM. However, research has shown that these single measurements are often unrepresentative of a patient’s status. In a study of 304 patients, at-home measurements indicated a different hypertension control status for approximately 30% of patients compared to in-clinic readings. This discrepancy is financially significant; moving from a 3.5- to a 4.0-star rating can be worth $800 million to $1 billion for a Medicare Advantage plan. Utilizing HBPM data could result in a 5% higher BP control rate, potentially unlocking quality bonus payments and providing a more accurate assessment of provider performance. The adoption of telemonitoring tools, such as the TeleHBPM platform, can facilitate this transition by providing high-quality longitudinal data for both clinical management and quality reporting.

For decades, ABPM has been considered the undisputed gold standard for out-of-office assessment, based on its ability to capture a 24-hour profile, including nocturnal readings and short-term variability, which offers a more comprehensive view of “BP load” than sporadic office visits. Consequently, international guidelines have long recommended ABPM for diagnosing hypertension and identifying high-risk circadian patterns.

Despite its dominance, ABPM faces significant practical and clinical challenges. Manufacturers were asking for high prices for their products, often exceeding 2,000 USD per unit. ABPM frequently has a negative impact on the patients’ quality of life. Furthermore, research has highlighted limited reproducibility; one-third of patients were inconsistently classified as “dippers” or “nondippers” between sessions, raising doubts about the stability of the risk markers.

Between 2018 and 2020, pivotal studies began to challenge ABPM’s prognostic superiority. Short-term variability in awake ABPM was found to be “nonpredictive” of recurrent stroke or cardiovascular events. In contrast, a study showed that a 5-minute assessment of beat-to-beat BPV and HBPM demonstrated strong and independent predictive power. This suggests that “noise” from physical activity during ABPM may obscure pathological variability, whereas HBPM provides a standardized resting-state data. The J-HOP study solidified this conceptual transition by comparing both modalities in 1,314 patients over 7 years. The findings were definitive: HBPV remained a significant predictor of cardiovascular risk, even after adjusting for ABPM values. Variability assessed by ABPM failed to show a significant relationship with prognosis after adjusting for the mean BP. HBPM captured cumulative hemodynamic instability over a week, avoiding the ” pseudovariability ” caused by irregular daily activities. Furthermore, HBPM correlates more strongly with biomarkers such as B-type natriuretic peptide, indicating that the heart is more sensitive to sustained day-to-day fluctuations than to transient 24-hour changes.

The paradigm shift was formally completed with the 2025 AHA/ACC Guidelines, which elevated HBPM to a central reference role. While acknowledging ABPM’s historical role, the guidelines now provide a Level 1A recommendation for HBPM as the preferred tool for long-term management and titration. This reflects the evidence that HBPM is more reproducible, accessible, and predictive of long-term cardiovascular outcomes than traditional methods.